Clairance de l'ARN du VHC après traitement par Interferon alpha chez des hémodialysés chroniques avec ou sans coinfection par le VHG/VHGB-C

Nephrologie

Volumn 18, Issue 7, 1997, Pages 281-286

  Rostaing, L ^a  

^a Clinique Saint Exupery   (France)

Author keywords

Alpha interferon; Chronic hemodialysis patients ; Hepatitis c ; Hepatitis g

Indexed keywords

AMINOTRANSFERASE; HEPATITIS C ANTIBODY; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HEMODIALYSIS; HEPATITIS C; HEPATITIS G VIRUS; HUMAN; KIDNEY TRANSPLANTATION; MALE; SUBCUTANEOUS DRUG ADMINISTRATION; SUPERINFECTION; VIRUS TYPING;

ADULT; FEMALE; FLAVIVIRIDAE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS, VIRAL, HUMAN; HUMANS; INTERFERON ALFA-2B; LIVER; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RENAL DIALYSIS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0031444120     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley El, Szmuness W, The dialysis vaccine trial study group. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984;311:496-501.
2. Alter MJ, Favero MS, Mayard JE. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. J Infect Dis 1986 ; 153 :1149-51.
3. Seaworth BJ, Garrett LE, Stead WW, Hamilton JD. Non-A, non-B hepatitis and chronic hemodialysis. Another dilemna. Am J Nephrol 1984 ;4:235-9.
4. Marches! D, Arid C, Poletti E, Mingardi G, Minola E, Mecca C. Outbreak of non-A, non-B hepatitis in centre haemodialysis patients : A retrospective analysis. Nephrol Dial Transpl 1988 ; 3:795-9.
5. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone drived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989 ; 244:359-62.
6. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegt-Meier GE, Bonino F, Colombo M, Lee WS, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M. An assay for circulatory antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 19S9 ; 244:362-4.
7. Allander T, Medin C, Jacobson SH,' Grillner L, Persson MAA. Hepatitis C transmission in a hemodialysis unit : Molecular evidence for spread of virus among patients not sharing equipment. J Med Virol 1994; 43:415-9.
8. Stuyver L, Claeys H, Wyseur A, van Arnhem W, De Beenhouwer H, Uytendaele S, Beckers J, Matthijs D, Leroux-Roels G, Maertens G, De Paepe M. Hepatitis C virus in a hemodialysis unit : Molecular evidence for nosocomial transmission. Kidney Int 1996 ; 49:889-95.
9. Sampietro M, Badalamenti S, Salvador! S, Corbetta N, Graziani G, Como G, Fiorelli G, Ponticelli C. High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit : Evidence for nosocomial transmission of HCV. Kidney Int 1995 ; 47:911-7.
10. Munro J, Briggs JD, McCruden EAB. Detection of a cluster of hepatitis C infections in a renal transplant unit by analysis of sequence variation of the NS5a gene. J Infect Dis 1996 ; 174:177-80.
11. Allander T, Gruber A, Naghari M, Beyene A, Soderstrom T, Bjorkholm M, Grillner L, Persson MAA. Fréquent patient to patient transmission of hepatitis C in a haematology ward. Lancet 1995; 345: 603-7.
12. Knudsen F, Wantzin P, Rasmussen K, Ladefoged SD, Lokkegaard N, Rasmussen LS, Lassen A, Krogsgaard K. Hepatitis C in dialysis patients: Relationship to blood transfusions, dialysis and liver disease. Kidney Int 1993; 21:288-91.
13. Lin DY, Lin HH, Huang CC, Liaw YE High incidence of hepatitis C infection in hemodialysis patients in Taiwan. Am J Kidney Dis 1993 ; 21:288-91.
14. Pol S, Romeo R, Zins B, Driss F, Lebkiri B, Carnot F, Berthclot P, Brechet C. Hepatitis C virus (HCV) RNA in anti-HCV positive hemodialyzed patients : Significance and therapeutic implications. Kidney Int 1993 ; 44:1097-100.
15. Gun JY, Lai YH, Yang CY, Chen SC, Chuang WL, Hsu TC, Chen HC, Chang WY, Tsai JH. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995 ; 69:459-65.
16. Simons JN, Leary TP, Dawson GJ, Pilot-Matias Tj, Muerhoff AS, Schlauder GG, Desai SM, Mushahwar IK. Isolation of novel virus-like sequences associated with human hepatitis. Nature Med 1995 ; 1:564-69.
17. Linnen J, Wages J, Zhang-Keck Z, Fry KE, Krawczynski KZ, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis S, Karayiannis P, Fung K, Nakatsuji Y, Shih JW, Young L, Piatak M, Hoover C, Fernandez J, Chen S, Zou J, Morris T, Hyams KG, Ismay S, Lifson JD, Hess G, Foung SKH, Thomas H, Bradley D, Margolis H, Kim JE Molecular cloning and disease association of hepatitis G virus : A transfusion-transmissible agent. Science 1996 ; 271:505-9.
18. Zuckerman AJ. The new GB hepatitis viruses. Lancet 1995 ; 345 : 1453-54.
19. Masuko D, Mitsui T, Iwano K, Yamasaki C, Okuda K, Meguro T, Murayama N, Inome T, Tsuda F, Okamoto H, Miyakawa Y, Mayumi M. Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med 1996 ; 334:1485-90.
20. Chan TM, Wu PC, Lau JYN, Lai CL, Lok ASF, Cheng IKP. Clinicopathologic features of hepatitis C virus infection in renal allograft recipients. Transplantation 1994 ; 58:996-1000.
21. Roth D, Zucker K, Cirocco R, De Mattos A, Burke GW, Nery J, Esquenazi V, Babischkin S, Miller J. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994 ; 45 :238-44.
22. Thervet E, Pol S, Legendre C, Gagnadoux MF, Cavalcanti R, Kreiss H. Low-dose recombinant leucocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients : A pilot study. Transplantation 1994 ; 58:625-8.
23. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995 ; 59:1426-31.
24. Magnone M, Holley JL, Shapiro R, Scantlebury V, Me Cauley J, Jordan M, Vivas C, Starzl T, Johnson UP. Interferona induced acute allograft rejection. Transplantation 1995 ; 59:1068-70.
25. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated by interferon alpha 2b for chronic hepatitis C. Nephron 1996 ; 74:512-6.
26. Koenig P, Vogel W, Umlauft F, Weyrer K, Prommegger R, Lhotta K, Neyer U, Stummvoll HK, Gruenewald K. Interferon treatment for chronic hepatitis C virus infection in urémie patients. Kidney Int 1994; 45:1507-9.
27. Ozyilkan E, Simsek H, Uzunalimoglu B, Telatar H. Interferon treatment of chronic active hepatitis C in patients with end-stage chronic renal failure. Nephron 1995 ; 71:156-9.
28. Raptopoulou-Gigi M, Spaia S, Garifallos A, Xenou P, Orphanou H, Zarafidou E, Petridon P, Vrettou M, Vagionas G, Galaktidou G, Marrondi I, Efkarpidou A, Kortsaris A. Interferon-o2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1995 ; 10:1834-37.
29. Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, Brechot C. Efficacy and tolerance of a-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995 ; 47:1412-8.
30. Young KK, Resnick RM, Myers TW. Detection of hepatitis C virus RNA by a combined reverse transcriptase-polymerase chain reaction assay. J Clin Microbiol 1993 ; 31:882-6.
31. Izopet J, Bogard M, Costes J, Duverlie G, Halfen Ph, Ouzan D, Puel J, Sayada C. Multicenter evaluation of analytical performance of the AmplicorTM HCV RNA qualitative assay. Hepatology 1994 ; 20 : 241 A.
32. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght V, Van Heuverswyn, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74:1093-102.
33. Simmonds P, Albert! A, Alter J, et al. A proposed system for the nomenclature of viral hepatitis C viral genotypes. Hepatology 1994 ; 19:1321-4.
34. Davis Gl, Baiart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa : A multicenter randomized, controlled trial. N Engl J Med 1989 ; 321:1501-6.
35. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C : A randomized, doubleblind, placebo-controlled trial. N Engl J Med 1989 ; 321:1506-10.
36. Hoofnagle JH. Therapy of acute and chronic viral hepatitis. Adv Intern Med 1994; 39:241-75.
37. Hoofnagle JH, Lau D. Chronic viral hepatitis - Benefits of current therapies. N Engl J Med 1996 ; 334:1470-1.
38. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, Benhamou JP, Erlinger S. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and inde-pendent prognostic factors of sustained response to Interferon alfa therapy in chronic hepatitis C. Hepatology 1995 ; 22:1050-6.
39. Hino K, Sainokami S, Shimoda K, liono S, Wang Y, Okamoto H, Miyakawa Y, et al. Genotypes and tilers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994 ; 42:299-305.
40. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994 ; 19:1088-94.
41. Buisson C, Degos F, Daniel F, Dupuy CA, Sari R, Simon N, Lemon nier C, Lebon P. Pharmacokinetics of interferon alpha-2b in hemodialysis. Nephrol Dial Transplant 1994 ; 9:977-8.
42. Kohara M, Tanaka T, Tsukiyama-Kohara K, Tanaka S, Mizokami M, Lau JYN, Hattori N. Hepatitis C virus genotypes 1 and 2 respond to interferon-a with different virologie kinetics. J Infect Dis 1995 ; 172 : 934-8.
43. Lau JYN, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993 ; 341:1501-4.
44. Orito E, Mizokami M, Nakano T, Terashima.H, Nojiri O, Sakakibara K, Mizuno M, Ogino M, Nakamura M, Matsumoto Y, Miyata KI, Lau JYN. Serum hepatitis C virus RNA levels as a predictor of subsequent response to interferon-a therapy in Japanese patients with chronic hepatitis C. J Med Virol 1994 ; 44:410-4.
45. Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, Diquattro O, Di Marco V, Loiacono O, Volpes R, Almasio P, Urdea MS, Neuwald P, Sanchez-Pescador R, Detmer J, Wilber JC, Pagliaro L. Hepatitis C viremia in chronic liver disease : Relationship to interferon-a orcorticosteroid treatment. Hepatology 1994 ; 19 : 273-9.
46. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, Shin S, Tanno M, Urdea MS, Kolberg JA. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995 ; 22:1351-4.
47. Izopet J, Payen JL, Alric L, Selves J, Dubois M, Henry S, Icart J, Mularczyk M, Barange K, Combis JM, Desmorat H, Vinel JP, SaintMarc-Girardin MF, Voigt JJ, Sayada C, Duffaut M, Pascal JP, Puel J. Baseline level and kinetics of HCV viremia during interferon therapy are related to HCV genotype. Hepatology 1995 ; 22:171 A.